I don’t see cardiac tissue adding much value to share price. My reasoning is simple. The only cost center generating cash flow seems to be the BioGlue cost center. I think that the cardiac tissue cost center operating margin is so low, that after subtracting the related operating expenses the tissue cost center has an operating loss. I don’t expect this to change. CRY has never, to my knowledge/recollection, ever said this cost center is currently profitable. CRY is welcome to bring clarification to this subject should they wish.
Dirty labs and a possible liability tail to boot? Not likely, but the probability is not zero either. So why take a big liability risk when this cost center is effectively just a gerbil wheel factory?
Amigo, check the numbers and then draw your own conclusions. You are responsible for doing your own due diligence.